Results 191 to 200 of about 50,850 (292)

PeakPASI as a marker of maximum psoriasis severity: a single‐center, cross‐sectional retrospective and questionnaire‐based study

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background The Psoriasis Area and Severity Index (PASI) is the standard measure for psoriasis severity but reflects only a single time point and may underestimate long‐term disease burden. To assess whether the highest‐ever recorded PASI (PeakPASI) can serve as a marker of historical disease severity and correlate with treatment burden and ...
Simran Wilkhoo, Stefanie Ziehfreund, Enya Müller, Hanna Wecker, Stefanie Eyerich, Tilo Biedermann, Alexander Zink   +6 more
wiley   +1 more source

High prevalence and distinct patterns of metabolic syndrome in rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis: a population-based study. [PDF]

Rheumatol Int
Williams JC, Rogers K, Southworth J, Hum RM, Ho P, Zhao SS.   +5 more
europepmc   +1 more source

S1 Guideline: Therapy of generalized pustular psoriasis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary The S1 guideline “Therapy of generalized pustular psoriasis (GPP)” is a German guideline developed in accordance with the criteria of the AWMF. The full version addresses clinical presentation, pathogenesis, diagnosis and differential diagnosis, comorbidities, and therapy.
Rotraut Mößner, Neda Cramer, Sascha Gerdes, Ulrike Hüffmeier, Andreas Körber, Kai Krause, Christian Kromer, Katharina Antonia Langen, Sandra Philipp, Knut Schäkel, Michael P. Schön, Michael Schultheis, Lukas Sollfrank, Petra Staubach, Michael Sticherling, Johannes Wohlrab, Dagmar Wilsmann‐Theis, Cornelia Paul   +17 more
wiley   +1 more source

Safety of Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Results from a Real-World Canadian Setting. [PDF]

Rheumatol Ther
Arendse R, Rahman P, Baer P, Haaland D, Bessette L, Sholter D, Rachich M, Rampakakis E, Marrache AM, Lehman AJ, Asin-Milan O.   +10 more
europepmc   +1 more source

Prevalence and factors associated with flares following COVID-19 mRNA vaccination in patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis: a national cohort study

, 2023
Fong W, Woon TH, Chew L, Low A, Law A, Poh Yj, Yeo SI, Leung YY, Ma M, Santosa A, Kong KO, Xu C, Teng GG, Mak A, Tay SH, Chuah TY, Roslan NE, Angkodjojo S, Phang KF, Sriranganat M, Tan TC, Cheung P, Lahiri M.   +22 more
europepmc   +1 more source

Serum extracellular matrix biomarkers in rheumatoid arthritis, psoriatic arthritis and psoriasis and their association with hand function. [PDF]

Sci Rep
Port H, Coppers B, Tragl S, Manger E, Niemiec LM, Bayat S, Simon D, Fagni F, Corte G, Bay-Jensen AC, Tascilar K, Hueber AJ, Schmidt KG, Schönau V, Sticherling M, Heinrich S, Leyendecker S, Bohr D, Schett G, Kleyer A, Holm Nielsen S, Liphardt AM.   +21 more
europepmc   +1 more source

Biogenesis of TNF‐α‐insights into proteostasis and inflammation

The FEBS Journal, EarlyView.
TNF‐α biogenesis, trafficking, and signalling are tightly and reciprocally coupled to cellular proteostasis systems, including ER chaperones and endoplasmic reticulum‐associated degradation. This bidirectional crosstalk determines whether TNF‐α responses are adaptive or proteotoxic.
Bailasan Haidar, Céline Philippe, Eric Chevet, Jiří Zahradník   +3 more
wiley   +1 more source

Safety Profile of Upadacitinib: Descriptive Analysis in Over 27,000 Patient-Years Across Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Atopic Dermatitis, and Inflammatory Bowel Disease. [PDF]

Adv Ther
Burmester GR, Deodhar A, Irvine AD, Panaccione R, Winthrop KL, Vleugels RA, Levy G, Suravaram S, Palac H, Wegrzyn L, Ford S, Meerwein S, Guttman-Yassky E.   +12 more
europepmc   +1 more source

Quantification of hand muscle volume and composition in patients with rheumatoid arthritis, psoriatic arthritis and psoriasis. [PDF]

BMC Musculoskelet Disord, 2020
Friedberger A, Figueiredo C, Grimm A, d'Oliveira I, Bäuerle T, Rech J, Kleyer A, Simon D, Uder M, Schett G, Engelke K.   +10 more
europepmc   +1 more source

Superior Clinical and Economic Value of IL‐23 Inhibitors Versus Adalimumab Biosimilars in Plaque Psoriasis

International Journal of Dermatology, EarlyView.
A bicentric retrospective real‐world study (N = 616) comparing IL‐23 inhibitors (guselkumab, risankizumab, tildrakizumab) with adalimumab biosimilars in moderate‐to‐severe plaque psoriasis. It presents PASI90 response at Weeks 16 and 52, NNT, and cost‐effectiveness (incremental cost per responder, CE plane, CEAC/CEAF).
Gennaro Marco Falco, Elena Ippoliti, Niccolò Gori, Giacomo Caldarola, Clara De Simone, Nicoletta Di Giorgi, Paulo Gabriel Longo, Marco Galluzzo, Luca Bianchi, Lorenzo Marcelli, Marina Talamonti, Maria Vittoria Cannizzaro, Lucia Di Nardo, Ketty Peris   +13 more
wiley   +1 more source